Oral Immunotherapy for Wheat Allergy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

April 13, 2017

Conditions
Wheat Allergy
Interventions
DRUG

Wheat OIT

Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.

Trial Locations (4)

21287

Johns Hopkins University School of Medicine, Baltimore

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

94305

Stanford University School of Medicine, Stanford

100029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Hugh A Sampson, MD

OTHER

NCT01980992 - Oral Immunotherapy for Wheat Allergy | Biotech Hunter | Biotech Hunter